Pfizer earnings jump on strong sales of Covid-19 products / Photo: Brendan Smialowski - AFP/File
-
Shares in Google owner Alphabet plummet on profit miss, ad slowdown
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US Fed holds interest rates steady despite 'too high' inflation
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
US labor leader Dolores Huerta dead: family
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
French firm Safran helps build aircraft wings of the future in UK factory
-
Canada hikes rates to contain oil price surge caused by Iran war
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Nintendo producer 'all nervous' as Zelda classic remake hits shelves
-
Billionaire Ambani's Jio soars in market debut after India's biggest IPO
-
Three killed by storm in southern India
-
AI chip giant SK hynix posts seven-fold surge in quarterly operating profit
-
Two hundred 'Cruise for life' passengers stranded in Cambodia
-
S.African activists push back on data centre rush
-
Billionaire Ambani's Jio jumps 21% in market debut after record India IPO
-
Billionaire Ambani's Jio to debut after record India IPO
-
Sri Lanka's Tamil farmers fight to reclaim land after civil war
-
UK set for cautious budget as borrowing costs climb
-
'They don't care about us': Trump food aid cuts leave Americans struggling and angry
-
US Fed expected to hold rates steady ahead of key midterm elections
-
Palestinian activist Khalil returns to Columbia after US detention
-
AI chip giant SK hynix says quarterly operating profit soars 630%
-
Youths testify about 'despair' in unprecedented Canadian climate trial
-
GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B
-
Charles tackles thorny legacy of slavery on Caribbean trip
Pfizer earnings jump on strong sales of Covid-19 products
Pfizer reported a jump in second-quarter profits Thursday behind a near doubling of revenues driven by sales of its Covid-19 vaccine and therapeutic drug Paxlovid.
The drugmaker raised some of its overall financial benchmarks, but maintained 2022 sales targets for its two Covid-19 products: $32 billion from the vaccine co-developed with German company BioNTech; and $22 billion from Paxlovid.
The total is equal to just over half of forecasted 2022 total revenues.
In the quarter ending June 30, profits were $9.9 billion, up 78 percent from the year-ago period following a 47 percent jump in revenues to $27.7 billion.
US officials last month approved emergency authorization to Pfizer and Moderna for Covid-19 vaccines in under-five-year-olds, the final age group awaiting immunization in most countries.
Pfizer is currently working on a Covid-19 Omicron vaccine booster candidate for the fall, assuming regulatory approval is granted, company officials said.
Pfizer and German BioNTech have also submitted data for an Omicron vaccine to the European Medicines Agency.
"Pfizer is well positioned to satisfy its current contractual obligations and potential demand within its production capacity through the end of the year," said Chief Executive Albert Bourla in a statement.
Sales for both its Covid-19 products rose during the quarter.
Revenues for the vaccine came in at $8.8 billion, up 13 percent from the year-ago period, while sales of Paxlovid were $8.1 billion -- a big jump over the prior quarter following a five-fold growth in US utilization.
Shares fell 0.2 percent to $51.43 in pre-market trading.
X.Wong--CPN